Expression of laminin-1 and matrix metalloproteinase-9 in benign and malignant endometrium.
Endometrium
endometrial hyperplasia
endometrial neoplasms
immunohistochemistry
laminin
matrix metalloproteinase 9
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
17
03
2022
accepted:
30
11
2022
entrez:
22
3
2023
pubmed:
23
3
2023
medline:
24
3
2023
Statut:
ppublish
Résumé
Laminin-1 and matrix metalloproteinase (MMP)-9 may play roles in the progression from benign to malignant endometrium, so we aimed to investigate their levels of expression in these tissues. This case-control study was conducted at a tertiary care center between January 2014 and December 2016. Paraffin blocks of 50 specimens of benign endometrium with proliferative (n = 20), secretory (n = 11), and atrophic (n = 5) endometrium; simple endometrial hyperplasia without atypia (n = 12); and endometrial polyp (n = 2) histology and 49 specimens of malignant endometrium with endometrioid (n = 40), serous (n = 7), clear cell (n = 1), and undifferentiated (n = 1) types were immunostained with laminin-1 and MMP-9 antibodies and assessed for basement membrane continuity for laminin-1 and the percentage and intensity of MMP-9 expression in epithelial cytoplasm. : Laminin-1 continuity in the basement membrane was higher in benign (92%) compared to malignant (16.3%) endometrium (p < 0.0001) without any difference between the subgroups within each group (p > 0.05). All atrophic endometria and endometrial polyps and 23.5% of low grade endometrioid and none of the other endometrial cancers showed uninterrupted basement membrane staining with laminin-1. All cases in malignant endometrium expressed MMP-9 with either low or high immunoreactivity while none of the cases in benign endometrium showed a high staining with MMP-9 (p < 0.01). Proliferative and hyperplastic endometrium together with grade 1 endometrioid cancer expressed MMP-9 better than the atrophic endometrium (p < 0.05). The immunoreactivity with MMP-9 increased gradually from secretory to hyperplastic endometrium and serous carcinoma (p < 0.05). MMP-9 expression in all types of cancers except grade 1 endometrioid and clear cell compared to proliferative endometrium was significantly higher (p < 0.05) and increased from proliferative to grade 2 endometrioid, grade 3 endometrioid, serous and undifferentiated endometrial carcinoma. Gradual increments in MMP-9 expression and basement membrane laminin-1 discontinuity may indicate progression from normal to hyperplastic and to low- and high-grade cancerous endometrium.
Sections du résumé
BACKGROUND
BACKGROUND
Laminin-1 and matrix metalloproteinase (MMP)-9 may play roles in the progression from benign to malignant endometrium, so we aimed to investigate their levels of expression in these tissues.
METHODS
METHODS
This case-control study was conducted at a tertiary care center between January 2014 and December 2016. Paraffin blocks of 50 specimens of benign endometrium with proliferative (n = 20), secretory (n = 11), and atrophic (n = 5) endometrium; simple endometrial hyperplasia without atypia (n = 12); and endometrial polyp (n = 2) histology and 49 specimens of malignant endometrium with endometrioid (n = 40), serous (n = 7), clear cell (n = 1), and undifferentiated (n = 1) types were immunostained with laminin-1 and MMP-9 antibodies and assessed for basement membrane continuity for laminin-1 and the percentage and intensity of MMP-9 expression in epithelial cytoplasm.
RESULTS
RESULTS
: Laminin-1 continuity in the basement membrane was higher in benign (92%) compared to malignant (16.3%) endometrium (p < 0.0001) without any difference between the subgroups within each group (p > 0.05). All atrophic endometria and endometrial polyps and 23.5% of low grade endometrioid and none of the other endometrial cancers showed uninterrupted basement membrane staining with laminin-1. All cases in malignant endometrium expressed MMP-9 with either low or high immunoreactivity while none of the cases in benign endometrium showed a high staining with MMP-9 (p < 0.01). Proliferative and hyperplastic endometrium together with grade 1 endometrioid cancer expressed MMP-9 better than the atrophic endometrium (p < 0.05). The immunoreactivity with MMP-9 increased gradually from secretory to hyperplastic endometrium and serous carcinoma (p < 0.05). MMP-9 expression in all types of cancers except grade 1 endometrioid and clear cell compared to proliferative endometrium was significantly higher (p < 0.05) and increased from proliferative to grade 2 endometrioid, grade 3 endometrioid, serous and undifferentiated endometrial carcinoma.
DISCUSSION
CONCLUSIONS
Gradual increments in MMP-9 expression and basement membrane laminin-1 discontinuity may indicate progression from normal to hyperplastic and to low- and high-grade cancerous endometrium.
Identifiants
pubmed: 36945954
doi: 10.55730/1300-0144.5568
pmc: PMC10388054
doi:
Substances chimiques
laminin 1
0
Matrix Metalloproteinase 9
EC 3.4.24.35
MMP9 protein, human
EC 3.4.24.35
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-159Références
Oncology. 1985;42(6):370-6
pubmed: 3906481
Cancer Microenviron. 2014 Aug;7(1-2):71-8
pubmed: 24858419
Hum Reprod. 2002 May;17(5):1189-98
pubmed: 11980737
Obstet Gynecol. 1987 May;69(5):794-9
pubmed: 2437505
Histopathology. 2007 Feb;50(3):348-57
pubmed: 17257130
J Clin Invest. 1994 Sep;94(3):946-53
pubmed: 8083380
J Reprod Fertil. 1999 Mar;115(2):225-32
pubmed: 10434927
Cancer Biol Ther. 2006 Jan;5(1):71-7
pubmed: 16322684
Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1911-7
pubmed: 17009991
Cancer. 2002 Mar 1;94(5):1466-75
pubmed: 11920503
Fertil Steril. 2001 Jan;75(1):152-9
pubmed: 11163831
Eur J Obstet Gynecol Reprod Biol. 2003 Dec 10;111(2):197-203
pubmed: 14597251
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S64-S74
pubmed: 30550484
Lancet. 1983 Feb 5;1(8319):296-7
pubmed: 6130313
Am J Pathol. 2004 Jul;165(1):83-94
pubmed: 15215164
Fertil Steril. 2019 Oct;112(4 Suppl1):e93-e115
pubmed: 31623748
Clin Chim Acta. 2000 Feb 15;291(2):113-35
pubmed: 10675719
Lab Invest. 1983 Aug;49(2):140-7
pubmed: 6348406
Cancer Lett. 2005 Jun 1;223(1):1-10
pubmed: 15890231
Hum Reprod. 2004 Jun;19(6):1257-64
pubmed: 15105396
J Cell Biol. 1990 Apr;110(4):1427-38
pubmed: 2324200
J Biol Chem. 1997 Mar 28;272(13):8270-5
pubmed: 9079647
Hum Pathol. 1997 Feb;28(2):220-6
pubmed: 9023406
Anticancer Res. 1999 Jul-Aug;19(4B):3067-71
pubmed: 10652594
Matrix Biol. 2003 Mar;22(1):35-47
pubmed: 12714040
Zhonghua Fu Chan Ke Za Zhi. 2002 Oct;37(10):604-7
pubmed: 12487935
J Cancer Res Clin Oncol. 2011 Feb;137(2):347-57
pubmed: 20425121
Dis Markers. 2012;32(5):321-7
pubmed: 22674412
Int J Mol Med. 2009 Feb;23(2):173-80
pubmed: 19148540
J Clin Pathol. 1987 Nov;40(11):1320-3
pubmed: 3693569
Hum Reprod. 2003 Mar;18(3):608-15
pubmed: 12615834
Gynecol Oncol. 2003 Aug;90(2):318-24
pubmed: 12893193
Eur J Clin Invest. 1999 Sep;29(9):793-801
pubmed: 10469168
Hum Reprod. 2002 Feb;17(2):284-8
pubmed: 11821264
Fertil Steril. 2001 Feb;75(2):288-96
pubmed: 11172829
J Reprod Fertil. 1996 May;107(1):43-51
pubmed: 8699433
Cell Adh Migr. 2013 Jan-Feb;7(1):150-256
pubmed: 23263633
Semin Cancer Biol. 2002 Jun;12(3):197-207
pubmed: 12083850
Asian Pac J Cancer Prev. 2013;14(3):2113-8
pubmed: 23679328
Cancers (Basel). 2019 Oct 23;11(11):
pubmed: 31652721
J Pathol. 2003 Jul;200(4):465-70
pubmed: 12845613
Cancer. 1988 Jul 1;62(1):142-9
pubmed: 3383111
Hum Reprod. 2006 Dec;21(12):3059-67
pubmed: 16880228
Eur J Cancer. 2002 Dec;38(18):2362-70
pubmed: 12460779
Tumori. 2002 Jul-Aug;88(4):296-9
pubmed: 12400981
Ann Anat. 2011 Feb 20;193(1):43-55
pubmed: 21145716
J Biol Chem. 1986 Feb 5;261(4):1883-9
pubmed: 3003087
Gynecol Oncol. 2004 Sep;94(3):699-704
pubmed: 15350361
Hum Reprod. 1999 Mar;14(3):793-9
pubmed: 10221716